Viveo

active

The Viveo Group, formerly known as Mafra Hospitalar, (“Mafra”, “Viveo”, or the “Company”) is an ecosystem of products and services for the health sector, with companies specialized in each link of the chain, dedicated on manufacturing and distribution of medical supplies and medicines in Brazil. Mafra was founded in 1996 as a medical supply distribution company. In 2018, Mafra verticalized its operations with the acquisition of Cremer, Brazil’s largest health consumables manufacturer and reseller (hospital gowns, bandages, gloves and masks). Besides consolidating the market through acquisitions, Viveo (new name as of January 2021) is a key player addressing the challenges resulting from the COVID-19 pandemic in Brazil.  The following companies are part of Viveo Group: -          Medical Distribution: Mafra Hospitalar, Cremer, Expressa, Tecnocold, Vitalab, Biogenetix, Byogene, -          Logistics Operation: Health Log-          Manufacturing: Cremer, Flexicotton-          Innovation: Far.Me.  There are five manufacturing facilities, 4 managed by Cremer and one by Flexicotton, which was acquired in late 2020. Four manufacturing facilities are located in the State of Santa Catarina and one in the State of Minas Gerais.  Viveo operates nine large distribution centers in the Brasilia/Federal District, Jundiai and Ribeirao Preto/Sao Paulo, Catalao/Goias, Indaial/Santa Catarina, Pouso Alegre/Minas Gerais, Londrina / Parana, Fortaleza/Ceara and Recife/Pernambuco. Cross-docking operations are located in Cajamar and Marilia in Sao Paulo State, Curitiba and Pato Branco/Parana and Lajeado/Rio Grande do Sul. With this infrastructure, Viveo services all capitals and major cities in Brazil.  The proposed IFC’s investment consists of an A Loan in the amount of USD 30 MM. The proposed investment will support Viveo’s response to COVID-19 and will include financing the capital expenditure of the Company related to the integration of recent acquisitions. Viveo will make investments in the manufacturing plants to improve the efficiency of production processes with new equipment and technology. The proposed investment will also be utilized for the Company’s working capital needs, generated by the growth plans of the Company (the “Project”).